Global Artificial Intelligence (AI) Partnering Deals Directory 2010-2022: Access to Terms and Agreements for 750+ Deals - Headline, Upfront, Milestone and Royalty Data

News provided by

Jun 09, 2022, 06:30 ET

DUBLIN, June 9, 2022 /PRNewswire/ -- The "Global Artificial Intelligence (AI) Partnering Terms and Agreements 2010 to 2022" report has been added to ResearchAndMarkets.com's offering.

This report contains a comprehensive listing of all artificial intelligence partnering deals announced since 2010 including financial terms where available including over 750 links to online deal records of actual artificial intelligence partnering deals as disclosed by the deal parties.

Trends in artificial intelligence partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Artificial intelligence partnering contract documents
Top artificial intelligence deals by value

The report provides a detailed understanding and analysis of how and why companies enter artificial intelligence partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors artificial intelligence technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest artificial intelligence, oligonucletides including aptamers agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

In addition, a comprehensive appendix is provided organized by artificial intelligence partnering company A-Z, deal type definitions and artificial intelligence partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in artificial intelligence partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of artificial intelligence technologies and products.

Report scope

Global Artificial Intelligence Partnering Terms and Agreements includes:

Trends in artificial intelligence dealmaking in the biopharma industry since 2010
Access to headline, upfront, milestone and royalty data
Access to over 750 artificial intelligence deals
The leading artificial intelligence deals by value since 2010
Most active artificial intelligence dealmakers since 2010
The leading artificial intelligence partnering resources

In Global Artificial Intelligence Partnering Terms and Agreements, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy and technology target

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in artificial intelligence dealmaking
2.1. Introduction
2.2. Artificial intelligence partnering over the years
2.3. Most active artificial intelligence dealmakers
2.4. Artificial intelligence partnering by deal type
2.5. Artificial intelligence partnering by therapy area
2.6. Deal terms for artificial intelligence partnering
2.6.1 Artificial intelligence partnering headline values
2.6.2 Artificial intelligence deal upfront payments
2.6.3 Artificial intelligence deal milestone payments
2.6.4 Artificial intelligence royalty rates

Chapter 3 - Leading artificial intelligence deals
3.1. Introduction
3.2. Top artificial intelligence deals by value

Chapter 4 - Most active artificial intelligence dealmakers
4.1. Introduction
4.2. Most active artificial intelligence dealmakers
4.3. Most active artificial intelligence partnering company profiles

Chapter 5 - Artificial intelligence contracts dealmaking directory
5.1. Introduction
5.2. Artificial intelligence contracts dealmaking directory

Chapter 6 - Artificial intelligence dealmaking by technology type

Appendices
Appendix 1 - Artificial intelligence deals by company A-Z
Appendix 2 - Artificial intelligence deals by stage of development
Appendix 3 - Artificial intelligence deals by deal type
Appendix 4 - Artificial intelligence deals by therapy area
Appendix 5 - Deal type definitions
Appendix 6 - Further reading on dealmaking

Table of figures
Figure 1: Artificial intelligence partnering since 2010
Figure 2: Active artificial intelligence dealmaking activity since 2010
Figure 3: Artificial intelligence partnering by deal type since 2010
Figure 4: Artificial intelligence partnering by disease type since 2010
Figure 5: Artificial intelligence deals with a headline value
Figure 6: Artificial intelligence deals with an upfront value
Figure 7: Artificial intelligence deals with a milestone value
Figure 8: Artificial intelligence deals with a royalty rate value
Figure 9: Top artificial intelligence deals by value since 2010
Figure 10: Most active artificial intelligence dealmakers since 2010

Companies Mentioned

HistoIndex
Medicines and Healthcare Products Regulatory Agency
Boehringer Ingelheim
Worthington Biochemical Corporation
Loop Insights
Roux Institute
Wyss Institute
Endpoint Health
EndPoint Technologies
MILA International
Lore IO
CoreBiome
Relation Therapeutics
DecisionQ
KBP BioSciences
AUM Biosciences
SOM Biotech
Vir Biotechnology
1ST Biotherapeutics
BurstIQ
Covaris
Genesis Therapeutics
C4X Discovery
Atomwise
IrisVision
PolarisQB
ChemDiv
Adaptive Biotechnologies
Kebotix
AltaML
Medial
Reveal Biosciences
Medial EarlySign
Global Good Fund
Mendel Health

For more information about this report visit https://www.researchandmarkets.com/r/7uulc

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets